Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
DUBLIN , Feb. 26, 2016 -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2015 on Thursday, March 3, 2016. The Company has scheduled a conference call for that same day, Thursday, March 3, 2016 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.
Interested parties can access the call by dialing:
| USA: | 1-844-861-5499 | |
| International: | 1-412-317-6581 | |
| Conference ID #: | 10081700 | |
A simultaneous webcast of the call can be accessed at:
https://www.webcaster4.com/Webcast/Page/1135/13669
A replay of the call can be accessed until March 10, 2016 by dialing:
| USA: | 1-877-344-7529 | |
| International: | 1-412-317-0088 | |
| Conference ID #: | 10081700 | |
The webcast of the call will be available for 30 days at:
https://www.webcaster4.com/Webcast/Page/1135/13669
About Trinity Biotech plc
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Contact: Trinity Biotech plc Kevin Tansley (353)-1-2769800 E-mail: [email protected] Lytham Partners LLC Joe Diaz, Joe Dorame & Robert Blum 602-889-9700
